Amylyx Stock: Why the Full Pipeline Story Matters
24/5 14:50
The idiom “never judge a book by its cover” can cut both ways when it comes to clinical-stage biotechnology companies like Amylyx Pharmaceuticals (NASDAQ: AMLX). The stock is up over 140% in the last 12 months as the company has made progress on its pipeline. One of the drugs i...